The field of high-density lipoprotein (HDL) therapeutics is broadly aimed at combating the
significant residual cardiovascular risk remaining after effective low-density lipoprotein (LDL) …

Atherosclerosis is the leading cause of heart disease, contributing to hundreds of thousands
of deaths annually. The use of long-term antilipid therapy has decreased low-density …

HDL-replacement therapy is a promising new treatment strategy involving the acute
administration of HDL to rapidly stabilize patients at imminent risk for developing a …

Opinion statement Statin therapy has been a significant advance in the management of
dyslipidemia and atherothrombotic cardiovascular disease with a resultant 30% to 40 …

New targets of high-density lipoprotein therapy : Current Opinion in Lipidology New targets of
high-density lipoprotein therapy : Current Opinion in Lipidology Log in or Register Subscribe to …

Since the discovery in the 1970s that plasma levels of high-density lipoprotein cholesterol
(HDL-C) are inversely associated with cardiovascular outcome, it has been postulated that …

Opinion statement The treatment of lipid abnormalities generally has focused on low-density
lipoprotein cholesterol (LDL-C) reduction based on extensive clinical trials and the National …

Many studies have suggested that a significant risk factor for atherosclerotic cardiovascular
disease (ASCVD) is low high-density lipoprotein cholesterol (HDL-C). Therefore, increasing …

The identification of an inverse association between high-density lipoprotein (HDL)
cholesterol levels and incident cardiovascular disease events, 1 combined with research on …

Purpose This article reviews therapies that affect HDLs. Findings Lipid-modifying agents in
current use (including statins, fibrates, and niacin) increase the concentration of HDL …